Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity
1998

Thalidomide and Its Analogues Enhance Anti-Tumour Activity of DMXAA

Sample size: 12 publication Evidence: moderate

Author Information

Author(s): L-M Ching, WL Browne, R Tchernegovski, T Gregory, BC Baguley, BD Palmer

Primary Institution: Auckland Cancer Society Research Centre, University of Auckland School of Medicine

Hypothesis

Does the inhibition of serum TNF production enhance the anti-tumour activity of DMXAA?

Conclusion

The study suggests that reducing serum TNF levels can improve the anti-tumour effects of DMXAA.

Supporting Evidence

  • Thalidomide potentiated the anti-tumour response of DMXAA when administered simultaneously.
  • Three analogues of thalidomide were more potent in inhibiting TNF production and enhancing anti-tumour activity.
  • Pentoxifylline also suppressed TNF production and increased the anti-tumour effect of DMXAA.

Takeaway

This study found that certain drugs can help a cancer treatment work better by lowering a harmful substance in the body.

Methodology

Mice with Colon 38 tumours were treated with DMXAA and thalidomide or its analogues, and tumour growth was measured.

Limitations

The differences in cure rates were not statistically significant, complicating the assessment of treatment efficacy.

Participant Demographics

C57B1/6 x DBA/2 F1 mice, aged 8-12 weeks.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication